More on Vertex Pharmaceuticals (VRTX): Q4 beats consensus estimates, but total revenue dropped...


More on Vertex Pharmaceuticals (VRTX): Q4 beats consensus estimates, but total revenue dropped by over 38% Y/Y on a plummet in Incivek sales, which came in at $222.8M versus $456.8M the previous year. In December of last year the Hep-C drug was hit by an FDA "Black Box" warning over a potentially fatal skin rash that could occur in patients taking the medication. Shares -2.5% AH.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs